1)執印太郎,篠原信雄,矢尾正祐,他:von Hippel-Lindau病全国疫学調査における腎癌の臨床的解析.日泌会誌 103:552-556,2012
2)Ishikawa I : Present status of renal cell carcinoma in dialysis patients in Japan : questionnaire study in 2002. Nephron Clin Pract 97:c11-c16,2004
3)国立がん研究センター:腎細胞がん.国立がん研究センターがん対策情報センターがん情報サービス(https://ganjoho.jp/public/cancer/renal_cell/index.html)(2020年8月25日アクセス)
4)日本泌尿器科学会,日本病理学会,日本医学放射線学会(編):腎癌取扱い規約,第4版.金原出版,2011
5)Zini L, Perrotte P, Capitanio U, et al : Radical versus partial nephrectomy : effect on overall and noncancer mortality. Cancer 115:1465-1471,2009
6)東京慈恵医科大学附属柏病院泌尿器科ホームページ:小径腎がん(http://www.jikei-uro.com/small_kidney_cancer/#kidney10)(2020年8月25日アクセス)
7)Méjean A, Ravaud A, Thezenas S, et al : Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med 379:417-427,2018
8)Naito S, Kinoshita H, Kondo T, et al : Prognostic factors of patients with metastatic renal cell carcinoma with removed metastases : a multicenter study of 556 patients. Urology 82:846-851,2013
9)Rini BI, Plimack ER, Stus V, et al : Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380:1116-1127,2019
10)Campbell SC, Novick AC, Belldegrun A, et al : Guideline for management of the clinical T1 renal mass. J Urol 182:1271-1279,2009
11)DeVita VT Jr HS, Rosenberg SA : Cancer Principles and Practice of Oncology. 8th Edition. Lippincott Williams & Wilkins, Philadelphia, PA, 2008